Blog

Shire's eye drug data could strengthen bid for Baxalta, says CEO

By Paul Sandle LONDON (Reuters) – Shire reported positive results for a new eye drug on Tuesday, increasing the chances of lifitegrast reaching the market next year and boosting the London-listed group’s prospects as it tries to buy Baxalta. Chief Executive Flemming Ornskov said the news would help Shire’s attempt at an equity-based takeover of its U.S. rival to create a global leader in treatments for rare diseases. Lifitegrast significantly

Fear not, eat bratwurst, says German food minister

Germany’s food and agriculture minister said Tuesday that people should not be afraid of biting into a grilled bratwurst despite the World Health Organization’s warning that sausages and ham cause cancer. “No one should be afraid when eating a bratwurst,” said Christian Schmidt. “We worry people unnecessarily if we put meat in the same category as asbestos or tobacco,” he added.

Braai-mad South Africa takes WHO meat warning with pinch of salt

Digesting news this week that the World Health Organization (WHO) had classified beef, lamb and pork as “probable” carcinogens, South Africans said they would take the risk rather than turn their backs on their nation’s social centerpiece. Afrikaans for barbecue, the open-air braai took root among Dutch settlers in the 1600s but over the next three centuries spread across South Africa’s many races as the way to eat and entertain

Wall St. drifts lower as weak earnings, crude weigh

Investors are also watching the Federal Reserve, which began its two-day policy meeting. While expectations of a rate hike this week are slim, traders will focus on the Fed’s statement on Wednesday for clues on the timing of a liftoff. All eyes are on Apple (AAPL.O), which reports fourth-quarter results after the close.

Wall St. drifts lower as weak earnings, crude weigh

Investors are also watching the Federal Reserve, which began its two-day policy meeting. While expectations of a rate hike this week are slim, traders will focus on the Fed’s statement on Wednesday for clues on the timing of a liftoff. All eyes are on Apple (AAPL.O), which reports fourth-quarter results after the close.